EIP Pharma, a Cambridge, Mass.-based therapeutics company focused on CNS diseases, completed $20.5m Series B financing.
The round was led by Access Industries.
The company intends to use the proceeds to further advance development of neflamapimod, an oral small molecule inhibitor of the intra-cellular enzyme p38 MAP kinase alpha (p38 alpha) being studied in Alzheimer’s disease.
Led by John Alam, M.D., CEO, EIP Pharma is a clinical-stage therapeutics company focused on CNS disorders. The company’s Neflamapimod – (previously VX-745, discovered by Vertex Pharmaceuticals) is an investigational drug to demonstrate the potential to reverse synaptic dysfunction and in turn improve episodic memory function in early Alzheimer’s disease. A Phase 2b double-blind, placebo-controlled study called REVERSE-SD is currently enrolling 150 patients.
The primary endpoint of REVERSE-SD is improvement in episodic memory, as assessed by the Hopkins Verbal Learning Test. Secondary endpoints include Clinical Dementia Rating Scale Sum-of-Boxes, Wechsler Memory Scale, and spinal fluid biomarkers of disease progression. Results from REVERSE-SD are expected to be available in the second half of 2019.
Neflamapimod was licensed by EIP Pharma in 2014.